Thanks@ContangoPhil
Looking forward to the December Interim Data , Company must believe SNT 5505 has the absolute best chance of attracting a partner or a licensing agreement promoting it as the lead candidate.
MC of only $60m with 3 Phase II in play is grossly undervalued ,, just one showing positive data should send us well up over $100m , 3 from 3 well that is what dreams are made of.
First value inflection point only 15 days away.... show me the money $$$$
Nice to pull another 9% gain on Friday ..
Tight Hands required ,,, make em pay to play from here on in ,,, if you need to sell some stock ,,, just load it and wait for the Buyers to pay your ask..
TBH as I stated before , i could see us around the 6c /7c mark as a solid base for the release of the data ...
Cash is always required with a non revenue Biotech ,, as long as its Higher than the previous CR or at a Premium ,,, I'll take my allocation on the next round.
SNT 6302,, First in Class,, Best in Class..... just my own opinion and I've been in the Biotech Investment space for over 20 years .... Results from that trial will set the SP on fire.... Dermal/Skin treatments are easily understood by Investors ,, the before and after photos are graphic ,,
The use on fresh surgical scars IMHO will show the greatest results preventing 99% of scaring,, Lacerations or Tearing always harder but as we have been made aware Fiona is already utilising SNT 6302 on fresh burn skin grafts....
I could see SNT 6302 becoming Standard of Care for every incision surgery and that market is colossal $$$$
Best of luck to all Holders NZT
Add to My Watchlist
What is My Watchlist?
